ABAli Asghar Bhutto

Ali Asghar Bhutto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ali Asghar Bhutto has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    NANOPARTICLE-DRIVEN WOUND HEALING: EXPLORING THE ANTIOXIDANT AND ANTIBACTERIAL POTENTIAL OF ZnO-BASED THERAPEUTICS

    by Ali Asghar Bhutto, Aseel A. Kadhem, Laraib Nawaz, Khalil Haider, Anirudh Gupta

    Background: Nanoparticles (NPs) have attracted considerable attention in contemporary biomedical research, especially for use in wound care. Among others, zinc oxide (ZnO) nanoparticles have shown promising antioxidant and antibacterial activities, making them ideal for wound healing and infection management. Because of their capacity to alleviate oxidative stress, defend against microbial infections, and stimulate cell regeneration, they have emerged as a novel therapeutic strategy in addressing wound healing concerns. Although they have potential, issues with toxicity, biocompatibility, and long-term stability remain to be addressed for medical applications of safe and effective nanocolloids. Objective: Here, we explore the antioxidant and antibacterial efficacy of ZnO nanoparticles to determine their potential as a therapeutic agent for wound healing. This review explores the ways ZnO nanoparticles promote tissue healing, their effect on microbial inhibition, and the barriers preventing clinical translation. This study also sheds light on possible approaches to enhance ZnO-based formulations for future biomedical applications. Methodology: We developed a structured questionnaire that was disseminated to healthcare professionals, biomedical researchers and nanotech experts to collect both quantitative and qualitative data. Data on awareness levels and perceptions regarding ZnO-based wound healing therapies and their safety and effectiveness were assessed. An extensive literature review was performed on peer-reviewed sources from PubMed, Scopus, Web of Science and Google Scholar to build a theoretical foundation for the biomedical application of ZnO nanoparticles. Key Findings: The results of the study showed that ZnO nanoparticles demonstrated an effective antibacterial activity against wound associated microorganisms, thus minimizing the chances of secondary infection. They also have anticancer and wound healing properties due to their antioxidant potential, which reduce oxidative stress, a critical contributor to delayed wound healing. The respondents endorsed the advantages offered by ZnO nanoparticles, as upregulation of fibroblast proliferation, matrix deposition, and overall enhancement of tissue regeneration. Nevertheless, issues surrounding cytotoxicity at elevated concentrations, stability in biological microenvironments, and aggregated body response (e.g., inflammation) still pose critical challenges. In addition, this investigation also added to the growing interest towards the development of biodegradable ZnO nanocomposites in order to investigate safety issues and increase their clinical relevance. Future Directions: Moreover, with potential and existing limitations need biocompatible ZnO with controlled release mechanisms to minimize toxicity and maximize therapeutic benefits. But it is possible that new improved advanced coating techniques, innovative hybrid nanomaterials, and tailored nanoparticle therapies can provide some answers to enhance specificity of drug delivery and wounds for instance. Rules and regulations should be established to guide the safe and ethical use of ZnO-based nanomedicine by regulatory agencies. Moreover, academic and industrial interdisciplinary collaboration between material scientists, medical experts, and pharmaceutical industries is also vital to transition ZnO nanoparticle studies to adoptable, scalable clinical wound healing therapies. Conclusion: ZnO nanoparticles are promising nanomedicine-driven wound healing agents with strong antioxidant and antibacterial properties leading to fast recovery and low chances of infection. They possess numerous advantages; however, further studies, optimization, and regulatory approvals of formulations are needed for their clinical translation. Combating with underlying difficulties and incorporating biocompatible nanotechnology, ZnO-directed therapeutics can systematically improve the key role of wound care and regenerative medicine in modern health care.


  • Open Access

    THE ROLE OF PHARMACISTS IN MANAGING GESTATIONAL DIABETES MELLITUS: A DESCRIPTIVE REVIEW

    by Rashid Ali, Ali Asghar Bhutto, Ibrahim Marouf Yasin Al Shyyab, Moiz Ali, Girma Tsega, Indrani Paul

    Background: The management of diabetes poses challenges due to the array of available medications and the absence of comprehensive comparative trials. To address this, the Spanish Diabetes Society commissioned a Working Group to create a dynamic document tailored to national context. Objective: The document emphasizes individualized treatment decisions by healthcare providers, considering patient characteristics and treatment safety. Regular updates ensure alignment with evolving evidence and expert insights. Key Aspects: Goals of Control: Initial treatment typically involves lifestyle modifications and metformin. For patients with HbA1c above 8.5%, insulin therapy may be initiated, possibly in combination with oral medications. Stepwise adjustments and close monitoring are essential to optimize patient outcomes and minimize complications. Inertia Therapy: Monitoring metabolic control, tolerance to treatment, and associated complications are crucial after therapy initiation. Regular reassessment and adjustments are necessary to maintain optimal control. Staggered Therapeutic Approaches: Medication choice is influenced by factors such as HbA1c levels, risk of hypoglycemia, and patient characteristics. Various alternatives to metformin, including sulfonylureas, DPP-4 inhibitors, glinides, thiazolidinediones, and basal insulin, are considered based on individual patient responses. Combination Therapies: Combinations of medications, such as metformin with sulfonylureas, DPP-4 inhibitors, or GLP-1 receptor agonists, are explored for efficacy and safety. Insulin therapy is considered in cases of poor metabolic control or intolerance to oral medications. Treatment Algorithms: Algorithms guide the sequential addition of medications based on patient response, aiming to achieve optimal metabolic control while minimizing adverse effects. Conclusion: The comprehensive framework outlined in the document aims to guide clinicians in navigating the complexities of diabetes management. It emphasizes individualized treatment approaches tailored to patient needs and safety considerations, with regular updates to reflect evolving evidence and expert consensus.

  • Open Access

    Determination of scums in medicine materials

    by Fiaz Ahmad, Sana Akhlaq, Ilyas Fiaz, Ali Asghar Bhutto, Ijaz Khan, Amina Ajmal, Junaid Ahmad

    The current study is describing the main degrading scums in bromazepam, diazepam, Cefixime trihydrate, cefazolin sodium, simvastatin, and lovastatin, among other materials and manufactured items. HPLC was used to characterize pharmaceutical substance scums by comparing their retention lengths to reference standards. Before deciding, they sorted all the material from its main scums. Scums fell between 1.23 to 20.57 min, and parent compounds had try values between 2.71 and 9.22. Thus, isolating and identifying these compounds takes 20 minutes. This study identified parent compounds and degradation products using HPLC after confirming the European Pharmacopeial methodology. HPLC method validation for parent pharmaceuticals and degradation scums examined specificity, linearity, precision, and accuracy. The process can be applied to commodities and waste products using each compound's values for these qualities. 98%–102% of parent and scum materials are recovered. The experimental technique repeats within 3%. In compliance with pharmacopeial and regulatory norms, scums above 0.1% must be determined for pharmaceutical safety, efficacy, and quality. It's vital due to the effects of packaging, transit, storage, and manufacturer synthetic pathways. Adjuvants may cause degradation scums. The selected drugs' raw material and finished product levels of their main degrading scums were examined, and a concentration range was provided.